These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31486705)

  • 21. Non-inferiority versus superiority drug claims: the (not so) subtle distinction.
    Ganju J; Rom D
    Trials; 2017 Jun; 18(1):278. PubMed ID: 28619049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mixed approach for proving non-inferiority in clinical trials with binary endpoints.
    Rousson V; Seifert B
    Biom J; 2008 Apr; 50(2):190-204. PubMed ID: 18311852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sample size considerations in active-control non-inferiority trials with binary data based on the odds ratio.
    Siqueira AL; Todd S; Whitehead A
    Stat Methods Med Res; 2015 Aug; 24(4):453-61. PubMed ID: 24492793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wald tests for variance-adjusted equivalence assessment with normal endpoints.
    Chen YM; Weng YT; Dong X; Tsong Y
    J Biopharm Stat; 2017; 27(2):308-316. PubMed ID: 27906607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Smooth Away From Expected (SAFE) non-inferiority frontier: theory and implementation with an application to the D3 trial.
    Quartagno M; Chan M; Turkova A; Ford D; White IR
    Trials; 2023 Aug; 24(1):556. PubMed ID: 37626423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple comparisons in non-inferiority trials: Reaction to recent regulatory guidance on multiple endpoints in clinical trials.
    Wiens BL
    J Biopharm Stat; 2018; 28(1):52-62. PubMed ID: 29065276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.
    Lafaye de Micheaux P; Liquet B; Marque S; Riou J
    J Biopharm Stat; 2014; 24(2):378-97. PubMed ID: 24605975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A more efficient three-arm non-inferiority test based on pooled estimators of the homogeneous variance.
    Lu H; Jin H; Zeng W
    Stat Methods Med Res; 2018 Aug; 27(8):2437-2446. PubMed ID: 27920362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evidential approach to non-inferiority clinical trials.
    Wang SJ; Blume JD
    Pharm Stat; 2011; 10(5):440-7. PubMed ID: 21928286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive clinical endpoint bioequivalence studies with sample size re-estimation based on a nuisance parameter.
    Zhu L; Sun W
    J Biopharm Stat; 2019; 29(5):776-799. PubMed ID: 31505986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints.
    Yang J; Li J; Wang S; Luo L; Liu P
    Hum Vaccin Immunother; 2019; 15(1):256-263. PubMed ID: 30273507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tests for equivalence or non-inferiority for paired binary data.
    Liu JP; Hsueh HM; Hsieh E; Chen JJ
    Stat Med; 2002 Jan; 21(2):231-45. PubMed ID: 11782062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combined superiority and non-inferiority approach to multiple endpoints in clinical trials.
    Bloch DA; Lai TL; Su Z; Tubert-Bitter P
    Stat Med; 2007 Mar; 26(6):1193-207. PubMed ID: 16791905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rethinking non-inferiority: a practical trial design for optimising treatment duration.
    Quartagno M; Walker AS; Carpenter JR; Phillips PP; Parmar MK
    Clin Trials; 2018 Oct; 15(5):477-488. PubMed ID: 29871495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-formulating non-inferiority trials as superiority trials: The case of binary outcomes.
    Durkalski VL; Berger VW
    Biom J; 2009 Feb; 51(1):185-92. PubMed ID: 19197960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On non-inferiority margin and statistical tests in active control trials.
    Chow SC; Shao J
    Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous confidence interval for assessing non-inferiority with assay sensitivity in a three-arm trial with binary endpoints.
    Tang N; Yu B
    Pharm Stat; 2020 Sep; 19(5):518-531. PubMed ID: 32112669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of vaccine equivalence/non-inferiority trials with correlated multiple binomial endpoints.
    Kong L; Kohberger RC; Koch GG
    J Biopharm Stat; 2006; 16(4):555-72. PubMed ID: 16892913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superiority inferences on individual endpoints following noninferiority testing in clinical trials.
    Logan BR; Tamhane AC
    Biom J; 2008 Oct; 50(5):693-703. PubMed ID: 18932132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.